3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
5
Neoplasms
3
Lymphoma
3
Preleukemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Precancerous Conditions
2
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphoid
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Leukemia, B-Cell
2
Leukemia
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Diseases
2
Esophageal Neoplasms
2
Bone Marrow Diseases
2
Sarcoma
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Second Primary
1
Neoplasms, Plasma Cell
1
Interventions
Dexamethasone
17
Lenalidomide
15
Bortezomib
12
Cyclophosphamide
7
fludarabine
6
carfilzomib
6
Melphalan
6
daratumumab
5
Calcium Dobesilate
5
pomalidomide
3
gamma-Globulins
3
fludarabine phosphate
3
belantamab mafodotin
3
Whole-Body Irradiation
3
Trimethoprim, Sulfamethoxazole Drug Combination
3
Tacrolimus
3
Mycophenolic Acid
3
isatuximab
2
elotuzumab
2
Sirolimus
2
Prednisone
2
Immunoglobulins, Intravenous
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Ciprofloxacin
2
Amoxicillin-Potassium Clavulanate Combination
2
venetoclax
1
thymoglobulin
1
siltuximab
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
Patient Reported Outcome Measures
×
1 year
×
Clear all
NCT05831787
2026-05-18
COSMIC
ASH Research Collaborative
Completed
201 enrolled
15 charts